TY - JOUR
T1 - Strategies for hepatitis C therapeutic intervention
T2 - Now and next
AU - Tan, Seng Lai
AU - He, Yupeng
AU - Huang, Ying
AU - Gale, Michael
PY - 2004/10
Y1 - 2004/10
N2 - Interferon-α-based therapies are the mainstay of hepatitis C treatment. However, these broad immunomodulatory agents, already limited by their side effects, expense and route of administration, are not efficacious in all cases. Therefore, research efforts have focused on identifying additional drugs and therapeutic modalities to benefit those individuals refractive to current therapy, and which might be more affordable, such as orally active small-molecule alternatives and preventive or therapeutic vaccines. It is likely that successful therapeutic intervention of hepatitis C will require a combination of approaches targeting different aspects of the viral life-cycle.
AB - Interferon-α-based therapies are the mainstay of hepatitis C treatment. However, these broad immunomodulatory agents, already limited by their side effects, expense and route of administration, are not efficacious in all cases. Therefore, research efforts have focused on identifying additional drugs and therapeutic modalities to benefit those individuals refractive to current therapy, and which might be more affordable, such as orally active small-molecule alternatives and preventive or therapeutic vaccines. It is likely that successful therapeutic intervention of hepatitis C will require a combination of approaches targeting different aspects of the viral life-cycle.
UR - http://www.scopus.com/inward/record.url?scp=16644390861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16644390861&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2004.07.003
DO - 10.1016/j.coph.2004.07.003
M3 - Review article
C2 - 15351350
AN - SCOPUS:16644390861
SN - 1471-4892
VL - 4
SP - 465
EP - 470
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
IS - 5
ER -
